Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Sells $1,470,000.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the completion of the sale, the chief executive officer now directly owns 660,482 shares in the company, valued at $32,363,618. This trade represents a 4.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kymera Therapeutics Stock Performance

NASDAQ KYMR traded down $0.04 during trading hours on Friday, hitting $47.62. 986,878 shares of the company traded hands, compared to its average volume of 611,517. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of -20.35 and a beta of 2.07. The business's 50-day moving average is $30.25 and its 200-day moving average is $35.78. Kymera Therapeutics, Inc. has a twelve month low of $19.45 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $22.10 million during the quarter, compared to analysts' expectations of $11.38 million. During the same period last year, the firm posted ($0.69) EPS. The firm's revenue for the quarter was up 114.6% compared to the same quarter last year. Analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Trading of Kymera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KYMR. Price T Rowe Associates Inc. MD lifted its position in shares of Kymera Therapeutics by 3.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company's stock valued at $276,395,000 after buying an additional 224,859 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Kymera Therapeutics by 13.0% during the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock worth $164,134,000 after acquiring an additional 689,547 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Kymera Therapeutics by 7.0% during the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company's stock worth $143,183,000 after acquiring an additional 344,080 shares in the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Kymera Therapeutics by 14.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock worth $207,184,000 after buying an additional 650,000 shares during the period. Finally, Siren L.L.C. increased its stake in Kymera Therapeutics by 9.1% in the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock worth $88,687,000 after purchasing an additional 270,580 shares during the period.

Wall Street Analysts Forecast Growth

KYMR has been the subject of a number of analyst reports. Bank of America raised Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective for the company in a research note on Monday, June 2nd. Stifel Nicolaus initiated coverage on Kymera Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price target for the company. JPMorgan Chase & Co. boosted their target price on Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a research report on Tuesday. Guggenheim reissued a "buy" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday. Finally, B. Riley raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $38.00 to $60.00 in a report on Tuesday. Two analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics has an average rating of "Moderate Buy" and an average target price of $59.82.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.